Heterocyclic degronimers for target protein degradation

US12076405B2 · kind B2 · utility

Assignee

• C4 THERAPEUTICS, INC.

Inventors

• Andrew J. Phillips · Arlington, US
• Christopher G. Nasveschuk · Stoneham, US
• James A. Henderson · Cambridge, US
• Yanke Liang · Belmont, US
• Mark Fitzgerald · Cambridge, US
• Minsheng He · Andover, US
• Ryan E. Michael · Newton, US

Key dates

• Filing date: Feb 1, 2021
• Grant date: Sep 3, 2024
• Expiry date: Sep 1, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.